Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for c…
The bill requires that most direct-to-consumer (DTC) advertisements for prescription drugs and biologicals covered by Medicare or Medicaid include a clear disclosure of the wholesale acquisition cost (WAC) for a 30-day supply or typical course of treatment. Drugs with a WAC under $35 are exempt.
Liberals emphasize consumer empowerment and Medicare savings benefits
Relative to its intended legislative type, this bill is a clear substantive statutory change that establishes a concrete obligation (wholesale acquisition cost disclosure) for direct-to-consumer prescription drug advertising, with defined exemptions, delegated rulemaking, and civil penalties.
The bill requires that most direct-to-consumer (DTC) advertisements for prescription drugs and biologicals covered by Medicare or Medicaid include a clear disclosure of the wholesale acquisition cost (WAC) for a 30-day supply or typical course of treatment.
Drugs with a WAC under $35 are exempt.
The Secretary of HHS must finalize rules within one year about how prices are displayed and timing for updates.
Relatively narrow, administrable consumer-transparency bill with bipartisan appeal in principle, but countervailing pharmaceutical industry resistance and implementation questions lower odds.
Relative to its intended legislative type, this bill is a clear substantive statutory change that establishes a concrete obligation (wholesale acquisition cost disclosure) for direct-to-consumer prescription drug advertising, with defined exemptions, delegated rulemaking, and civil penalties. It integrates with existing statutory definitions and enforcement procedures but defers many presentation, operational, fiscal, and edge-case details to the Secretary's forthcoming regulations.
Liberals emphasize consumer empowerment and Medicare savings benefits
These are examples from the analysis, not a ranked list of the most-affected groups.
Liberals emphasize consumer empowerment and Medicare savings benefits
Likely supportive overall because the bill increases price transparency for consumers and may curb wasteful public spending.
Might push for stronger, more consumer-relevant disclosures such as expected out-of-pocket costs or applicability to broader drug categories.
Sees the bill as a modest federal action to inform patients and potentially reduce unnecessary high-cost prescribing.
Cautiously favorable: appreciates consumer information and potential savings for taxpayers, but wants careful rulemaking to avoid confusion.
Will emphasize practical implementation details, administrative feasibility, and minimizing unintended consequences.
Likely to seek clear guidance on how WAC is presented and safeguards against consumer misunderstanding.
Likely skeptical or opposed because the bill imposes new federal regulation on commercial speech and advertising practices.
Views include concerns about government overreach, added compliance costs, and potential chilling effects on pharmaceutical communication.
May argue the disclosure could be misleading and interfere with market signals rather than improve consumer outcomes.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Relatively narrow, administrable consumer-transparency bill with bipartisan appeal in principle, but countervailing pharmaceutical industry resistance and implementation questions lower odds.
The bill has not accumulated any surfaced votes yet.
Liberals emphasize consumer empowerment and Medicare savings benefits
Relatively narrow, administrable consumer-transparency bill with bipartisan appeal in principle, but countervailing pharmaceutical industry…
Relative to its intended legislative type, this bill is a clear substantive statutory change that establishes a concrete obligation (wholesale acquisition cost disclosure) for direct-to-consumer prescription drug advert…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.